US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Investigator sponsored Phase I/II study of AXL1717 in patients with brain tumors started in the US

STOCKHOLM, January 21, 2013. Axelar AB, a Karolinska Development AB portfolio company, announced today that an investigator sponsored Phase I/II study with AXL1717 in patients with malignant astrocytomas, a type of brain tumor, has commenced in the United States.The study is conducted at the Rush University Medical Center in Chicago in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma), with AXL1717 - an oral small-molecule insulin-like Growth Factor 1 (IGF-1) receptor inhibitor - as the investigational drug. Astrocytoma represents about

Axelar AB appoints Carl Harald Janson as CEO

STOCKHOLM, October 1, 2012. Axelar AB, a Karolinska Development AB portfolio company, announced today the appointment of Carl Harald Janson as new CEO.“We are very pleased to have appointed Carl Harald Janson as our new CEO in Axelar AB”, says Göran Pettersson, Chairman of Axelar. “Carl Harald has previously been a Member of the Board of Axelar. His broad experience in pharmaceutical development will be of great benefit to the company. Johan Harmenberg, CEO of Axelar since 2007, will continue as Chief Medical Officer.” “I am excited to lead the experienced team of Axelar and to continue

Axelar AB has presented Phase I/II data of AXL1717 at the American Society of Clinical Oncology (ASCO) Annual Meeting

STOCKHOLM, June 2, 2012. Axelar AB, a Karolinska Development AB portfolio company, today announced the release of a poster at The American Society of Clinical Oncology (ASCO) Annual Meeting with data from the Phase I/II trial of AXL1717 that was completed in 2011.The poster entitled “A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A Phase I clinical trial.” is available on the Axelar and Karolinska Development websites (www.axelar.se and www.karolinskadevelopment.com). For further

Axelar to present at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2012

STOCKHOLM, May 15, 2012. Axelar AB, a Karolinska Development portfolio company, today announces that a poster will be presented at the ASCO meeting in Chicago, Illinois, USA in June 2012, containing data from the clinical phase I/II trial in cancer patients that was completed in 2011.The abstract of the poster is entitled “A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A phase I clinical trial” (Abstract # 93571) and will be available from Wednesday, May 16, 2012 at 6.00 PM (EDT) on

Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer

STOCKHOLM, SWEDEN - December 28, 2011. Axelar AB, a Karolinska Development AB portfolio company, today announces that the first patient has been dosed in a randomized Phase II study on non-small cell lung cancer (NSCLC) patients of its drug candidate AXL1717.AXL1717 is the first targeted oral small-molecule Insulin-like Growth Factor 1 (IGF-1) receptor inhibitor clinically tested which does not affect the closely-related insulin receptor. In the recently completed Phase I/II study, AXL1717 demonstrated a good safety profile and signs that suggest clinical benefit were observed in some

Axelar reports good safety profile of AXL1717 in Phase I/II in cancer patients - Poster now published on the company's website

STOCKHOLM, SWEDEN - September 26, 2011. Axelar AB, a Karolinska Development AB portfolio company, today released results of the completed Phase I/II clinical safety study for its drug candidate AXL1717 at the European Multidisciplinary Cancer Congress (ESMO) meeting in Stockholm, Sweden. As reported earlier today, all major objectives were met in the study and signs that suggest clinical benefit were observed in some patients with non-small cell lung cancer. The poster is now available on Axelar's and Karolinska Development's website.For further information, please contact:Johan

Axelar reports good safety profile of AXL1717 in Phase I/II in cancer patients

STOCKHOLM, SWEDEN - September 26, 2011. Axelar AB, a Karolinska Development AB portfolio company, today releases results of the completed Phase I/II clinical safety study for its drug candidate AXL1717 at the European Multidisciplinary Cancer Congress (ESMO) meeting in Stockholm, Sweden. All major objectives were met in the study and signs that suggest clinical benefit were observed in some patients with non-small cell lung cancer.AXL1717 is the first targeted oral small-molecule Insulin-like Growth Factor 1 (IGF-1) receptor inhibitor clinically tested which does not affect the closely-

Axelar reports completion of the Phase I/II safety study with AXL1717 in cancer patients

STOCKHOLM, SWEDEN - July 7, 2011. Axelar AB, a Karolinska Development portfolio company, today announced the completion of the Phase I/II clinical safety trial carried out in Sweden in patients with solid tumors. The preliminary results of the study will be presented at the European Multidisciplinary Cancer Congress (ESMO) meeting in Stockholm, Sweden, on September 26, 2011.Axelar's drug candidate, AXL1717, was administered to a total of 49 advanced-stage cancer patients with progressive solid tumors and no remaining treatment options. The open label safety trial consisted of three parts; a

Axelar secures funding for the coming Phase II program in lung cancer

STOCKHOLM, SWEDEN, May 11, 2011. Axelar AB, a Karolinska Development portfolio company, today announced that it has secured SEK 123m (EUR 13.7m) which will allow Axelar to complete its coming Phase II program in patients suffering from non-small cell lung cancer (NSCLC). Data from the ongoing Phase I/II trial will be presented later this year.The financing round was directed to a syndicate of investors including its current major owner Karolinska Development. Axelar recently reported promising interim data from the first part of the Phase I/II study. AXL1717 has shown excellent tolerability

Axelar announces positive interim results in Phase I/II study

STOCKHOLM, SWEDEN, APRIL 6, 2011. Axelar AB, a Karolinska Development portfolio company, today announces positive results from the completed first part of the combined Phase I/II clinical trial, evaluating AXL1717 as a new treatment for solid tumors. The study has successfully reached its primary endpoint, identifying the recommended Phase II dose as well as provided evidence that AXL1717 is safe and tolerable. Furthermore, data also supports Axelar's strategy to target AXL1717 in patients with squamous non-small cell lung cancer. Results will be presented later this year.In the ongoing

First AXL1717 clinical data from ongoing phase I/II study in cancer patients has been published

STOCKHOLM, September 7, 2010. Axelar AB today announces that the first submitted medical article on the ongoing phase I/II cancer study with AXL1717 has been published in Acta Oncologica.The article, including clinical data from a limited group of AXL1717-treated patients, by Drs. Ekman, Bergqvist, Frödin and colleagues, was recently published in Acta Oncologica, Early Online 1-7, 2010. The publication describes four heavily pretreated patients with progressive and advanced squamous non-small cell lung cancer (NSCLC) without any remaining therapeutic options. The patients were treated with

AXL1717 clinical data from ongoing phase I/II study in cancer patients will be released in connection with the ASCO meeting in Chicago, June 2010

STOCKHOLM, May 17, 2010. Axelar AB, a Karolinska Development portfolio company, today announces that a submitted abstract has been accepted to the ASCO meeting in Chicago, June 2010.The abstract containing preliminary clinical data will be publicly released on ASCO's website, www.asco.org  on Thursday, May 20, 2010 at 6:00 PM (EDT)."We are pleased that the abstract containing a preliminary update of the favorable clinical data has been accepted by 2010 Annual Meeting of the American Society of Clinical Oncology", says Johan Harmenberg, CEO Axelar AB. For further information, please

Axelar's board strengthened

April 27, 2010 - Axelar AB, a Karolinska Development portfolio company, today announces that Göran Pettersson has been elected new chairman of the board and Ingemar Kihlström board member. Both have vast international experience from leading positions in the pharmaceutical industry."We have just secured 25 MSEK financing for the continued development of Axelar's anticancer compound "AXL1717". It's encouraging that we at the same time are able to further strengthen the board with Göran and Ingemar, both having so much international experience from the pharmaceutical industry. They will

Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

STOCKHOLM, SWEDEN - 13 November 2009 - Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA. The clinical trial is being conducted in Sweden on advanced-stage cancer patients with documented progressive solid tumors and no remaining treatment options. The first part of the trial has been successfully

Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717

Stockholm, Sweden 2008-06-17 - STOCKHOLM, SWEDEN - Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an insulin-like growth factor- 1 (IGF-1) receptor inhibitor. The phase I/II clinical trial is primarily designed to assess the  safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects will be documented whenever possible and the study will be conducted in Sweden.See PDF

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media